6. Anti-infective medicines

6.2. Antibacterials

6.2.2. Watch group antibiotics

Ceftriaxone

**Indication**
Necrotising fasciitis  
**ICD11 code**: 1B71.Z

**INN**
Ceftriaxone

**Medicine type**
Chemical agent

**Antibiotic groups**
WATCH

**List type**
Core

**Formulations**
Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt) (EML)

**EML status history**
First added in 2021 (TRS 1035)  
Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions  
Read more about patents.

**Wikipedia**
Ceftriaxone

**DrugBank**
Ceftriaxone

---

**Expert Committee recommendation**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.
- replacing the oral liquid formulation of clindamycin (oral liquid 75 mg/5 mL) with powder for oral liquid 75 mg/5 mL (as palmitate hydrochloride) on the EML and EMLc.
- the addition of new strength formulations of IV vancomycin (500 mg, 1 g (as hydrochloride) on the EMLc.

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended that the range of strengths of metronidazole tablets be replaced with reference to specific strengths on the EML and EMLc.

**EML recommendations: Necrotising fasciitis**

**First choice**
- metronidazole  
  co-prescribed with ceftriaxone

**Second choice**
- clindamycin  
  co-prescribed with piperacillin + tazobactam
- vancomycin